Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin D Bunker

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Molecular Cancer Therapeutics|December 12, 2025
The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Anti-Tumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer ModelsJianhui Ma, Sayee Hegde, Masha Sergeeva, et al.
Journal of Medicinal Chemistry|August 23, 2021
Discovery of ZN-c3, a Highly Potent and Selective Wee1 Inhibitor Undergoing Evaluation in Clinical Trials for the Treatment of CancerPeter Q Huang, Brant C Boren, Sayee G Hegde, et al.
Physiological Reports|November 17, 2025
Effects of a novel acetaminophen analog on cardiorespiratory compensatory responses and survival in a male rat model of traumatic hemorrhageMiryam M Pando, Kathy L Ryan, Mariam L Calderon, et al.
Journal of Medicinal Chemistry|July 14, 2025
Discovery of ZN-c5, an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) with Improved PharmacokineticsSayee G Hegde, Peter Q Huang, Kevin D Bunker, et al.
Molecular Cancer Therapeutics|April 15, 2025
Azenosertib is a potent and selective WEE1 kinase inhibitor with broad antitumor activity across a range of solid tumorsJianhui Ma, Wen Liu, Jiali Li, et al.
NPJ Precision Oncology|January 4, 2025
Cyclin E1/CDK2 activation defines a key vulnerability to WEE1 kinase inhibition in gynecological cancersDaehwan Kim, Heekyung Chung, Wen Liu, et al.
Journal of Medicinal Chemistry|January 18, 2014
Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinibQinhua Huang, Ted W Johnson, Simon Bailey, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Molecular Cancer Therapeutics|December 12, 2025
The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Anti-Tumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer ModelsJianhui Ma, Sayee Hegde, Masha Sergeeva, et al.
Journal of Medicinal Chemistry|August 23, 2021
Discovery of ZN-c3, a Highly Potent and Selective Wee1 Inhibitor Undergoing Evaluation in Clinical Trials for the Treatment of CancerPeter Q Huang, Brant C Boren, Sayee G Hegde, et al.
Physiological Reports|November 17, 2025
Effects of a novel acetaminophen analog on cardiorespiratory compensatory responses and survival in a male rat model of traumatic hemorrhageMiryam M Pando, Kathy L Ryan, Mariam L Calderon, et al.
Journal of Medicinal Chemistry|July 14, 2025
Discovery of ZN-c5, an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) with Improved PharmacokineticsSayee G Hegde, Peter Q Huang, Kevin D Bunker, et al.
Molecular Cancer Therapeutics|April 15, 2025
Azenosertib is a potent and selective WEE1 kinase inhibitor with broad antitumor activity across a range of solid tumorsJianhui Ma, Wen Liu, Jiali Li, et al.
NPJ Precision Oncology|January 4, 2025
Cyclin E1/CDK2 activation defines a key vulnerability to WEE1 kinase inhibition in gynecological cancersDaehwan Kim, Heekyung Chung, Wen Liu, et al.
Journal of Medicinal Chemistry|January 18, 2014
Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinibQinhua Huang, Ted W Johnson, Simon Bailey, et al.
Pageof 2